ulcerative colitis and semaglutide The alleviating effect mechanism of GLP-1 on Semaglutide-Induced Small Bowel Pseudo-Obstruction and

Cell Metab 34(7):10541063 e1057

Selective expansion of polyfunctional pathogen-specific cd4(+) T cells in hiv-1-infected patients with immune reconstitution inflammatory syndrome

Semaglutide: Linear polypeptide PEPTIDE SEQUENCE Cagrilintide: ?Glu-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH 2 Semaglutide: H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CHEMICAL STRUCTURE Cagrilintide: Semaglutide: CHEMICAL STRUCTURE Cagrilintide: C 194 H 312 N 54 O 59 S 2 Semaglutide: C 187 H 291 N 45 O 59 Mechanism of Action Cagrilintide acts primarily as a long-acting amylin analogue, stimulating amylin and calcitonin receptors to promote satiety, slow gastric emptying, and suppress postprandial glucagon release

The titration started at 0.25 mg of each compound and stepped up every 4 weeks

Semaglutide has consistently demonstrated significant weight loss effects in clinical trials

On the other hand, the cardiovascular destiny of the diabetic patient is not unavoidable, as patients with type 2 diabetes (T2D) who had major risk factors for cardiovascular disease (CVD) within the target range had little or no excess risk of CVD and mortality [4]